MXPA04001256A - Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso. - Google Patents

Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.

Info

Publication number
MXPA04001256A
MXPA04001256A MXPA04001256A MXPA04001256A MXPA04001256A MX PA04001256 A MXPA04001256 A MX PA04001256A MX PA04001256 A MXPA04001256 A MX PA04001256A MX PA04001256 A MXPA04001256 A MX PA04001256A MX PA04001256 A MXPA04001256 A MX PA04001256A
Authority
MX
Mexico
Prior art keywords
active ingredients
aryl substituted
combination preparations
propanolamine derivatives
substituted propanolamine
Prior art date
Application number
MXPA04001256A
Other languages
English (en)
Inventor
Frick Wendelin
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140170A external-priority patent/DE10140170A1/de
Priority claimed from DE2001142455 external-priority patent/DE10142455A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA04001256A publication Critical patent/MXPA04001256A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invencion se refiere a mezclas de derivados de propanolamina de la Formula (I), en donde los radicales tienen los significados citados en la descripcion, ademas de sus sales fisiologicamente compatibles, con derivados fisiologicamente funcionales.
MXPA04001256A 2001-08-22 2002-08-09 Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso. MXPA04001256A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10140170A DE10140170A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von arylsubstituierten Propanolaminderivaten mit weiteren Wirkstoffen und deren Verwendung
DE2001142455 DE10142455A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von arylsubstituierten Propanolderivaten mit weiteren Wirkstoffen und deren Verwendung
PCT/EP2002/008907 WO2003018059A2 (de) 2001-08-22 2002-08-09 Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung

Publications (1)

Publication Number Publication Date
MXPA04001256A true MXPA04001256A (es) 2004-05-27

Family

ID=26009945

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001256A MXPA04001256A (es) 2001-08-22 2002-08-09 Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.

Country Status (21)

Country Link
US (1) US20030158094A1 (es)
EP (1) EP1420826A2 (es)
JP (1) JP2005505538A (es)
KR (1) KR20040027963A (es)
CN (1) CN1638801A (es)
AR (1) AR035284A1 (es)
BR (1) BR0211995A (es)
CA (1) CA2457974A1 (es)
CO (1) CO5560569A2 (es)
HR (1) HRP20040172A2 (es)
HU (1) HUP0401908A2 (es)
IL (1) IL160475A0 (es)
MX (1) MXPA04001256A (es)
NO (1) NO20040726L (es)
NZ (1) NZ531292A (es)
PA (1) PA8553101A1 (es)
PE (1) PE20030358A1 (es)
PL (1) PL366855A1 (es)
RU (1) RU2004108120A (es)
UY (1) UY27418A1 (es)
WO (1) WO2003018059A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
IN2014DN03093A (es) 2011-10-24 2015-05-15 Mannkind Corp
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU779264B2 (en) * 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications

Also Published As

Publication number Publication date
BR0211995A (pt) 2004-09-28
HRP20040172A2 (en) 2004-10-31
IL160475A0 (en) 2004-07-25
RU2004108120A (ru) 2005-04-10
HUP0401908A2 (hu) 2005-01-28
US20030158094A1 (en) 2003-08-21
AR035284A1 (es) 2004-05-05
EP1420826A2 (de) 2004-05-26
WO2003018059A3 (de) 2003-11-13
KR20040027963A (ko) 2004-04-01
WO2003018059A2 (de) 2003-03-06
CN1638801A (zh) 2005-07-13
UY27418A1 (es) 2002-11-29
CO5560569A2 (es) 2005-09-30
NZ531292A (en) 2005-08-26
PL366855A1 (en) 2005-02-07
CA2457974A1 (en) 2003-03-06
NO20040726L (no) 2004-02-19
PE20030358A1 (es) 2003-04-23
PA8553101A1 (es) 2003-06-30
JP2005505538A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
SE0001899D0 (sv) New compounds
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY143795A (en) Tetrahydropyridoindole derivatives
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
HUP0102521A2 (hu) Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
GB0114286D0 (en) Nucleoside Derivatives
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
MY133969A (en) Indoloquinazolinones
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
MXPA04001773A (es) Derivados de 6,7-dihidroxitetrahidroisquinolinas 3-sustituidas parta uso como agentes antibacterianos.
MXPA03011128A (es) Composicion de sabor y fragancia.
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
TW200504051A (en) Novel acridine derivatives and their use as medicaments